These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16958135)

  • 61. Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design.
    Ozen A; Sherman W; Schiffer CA
    J Chem Theory Comput; 2013 Dec; 9(12):5693-5705. PubMed ID: 24587770
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern.
    Ozen A; Haliloğlu T; Schiffer CA
    J Chem Theory Comput; 2012 Feb; 8(2):. PubMed ID: 24348205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of Hepatitis C Virus Infection with Type II Diabetes in Ethiopia: A Hospital-Based Case-Control Study.
    Ali S; Abera S; Mihret A; Abebe T
    Interdiscip Perspect Infect Dis; 2012; 2012():354656. PubMed ID: 23049551
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Zebrafish as a potential model organism for drug test against hepatitis C virus.
    Ding CB; Zhang JP; Zhao Y; Peng ZG; Song DQ; Jiang JD
    PLoS One; 2011; 6(8):e22921. PubMed ID: 21857967
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of immunogenic regions within the alternative reading frame protein of hepatitis C virus (genotype 3).
    Qureshi H; Qazi R; Hamid S; Qureshi SA
    Eur J Clin Microbiol Infect Dis; 2011 Sep; 30(9):1075-83. PubMed ID: 21318731
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.
    Romano KP; Ali A; Royer WE; Schiffer CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(49):20986-91. PubMed ID: 21084633
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hepatitis C virus genomic RNA dimerization is mediated via a kissing complex intermediate.
    Shetty S; Kim S; Shimakami T; Lemon SM; Mihailescu MR
    RNA; 2010 May; 16(5):913-25. PubMed ID: 20360391
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HCV drug discovery aimed at viral eradication.
    Schinazi RF; Bassit L; Gavegnano C
    J Viral Hepat; 2010 Feb; 17(2):77-90. PubMed ID: 20040045
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatitis C therapy--the future looks bright.
    Qureshi SA; Qureshi H; Hameed A
    Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1409-13. PubMed ID: 19727870
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Screening a peptide library by DSC and SAXD: comparison with the biological function of the parent proteins.
    Pérez-Berná AJ; Pabst G; Laggner P; Villalaín J
    PLoS One; 2009; 4(2):e4356. PubMed ID: 19194494
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Natural products as promising drug candidates for the treatment of hepatitis B and C.
    Wohlfarth C; Efferth T
    Acta Pharmacol Sin; 2009 Jan; 30(1):25-30. PubMed ID: 19060918
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interaction of the most membranotropic region of the HCV E2 envelope glycoprotein with membranes. Biophysical characterization.
    Pérez-Berná AJ; Guillén J; Moreno MR; Gómez-Sánchez AI; Pabst G; Laggner P; Villalaín J
    Biophys J; 2008 Jun; 94(12):4737-50. PubMed ID: 18339752
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatitis C virus core protein binding to lipid membranes: the role of domains 1 and 2.
    Pérez-Berná AJ; Veiga AS; Castanho MA; Villalaín J
    J Viral Hepat; 2008 May; 15(5):346-56. PubMed ID: 18179451
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quasispecies and its impact on viral hepatitis.
    Domingo E; Gomez J
    Virus Res; 2007 Aug; 127(2):131-50. PubMed ID: 17349710
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon.
    Qureshi SA
    Med Res Rev; 2007 May; 27(3):353-73. PubMed ID: 16958135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rapid virologic response: a new milestone in the management of chronic hepatitis C.
    Poordad F; Reddy KR; Martin P
    Clin Infect Dis; 2008 Jan; 46(1):78-84. PubMed ID: 18171217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.